Velimogene aliplasmid

Bibliography

• Coley W. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci 1893;105:487-511
   Google Scholar
• Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994;64:529-64
   PubMed Web of Science ®Google Scholar
• Coley W. The treatment of malignant inoperable tumors with the mixed toxins of erysipelas and Bacillus prodigiosus. M Weissenbruch, Brussels; 1914
   Google Scholar
• Lamm DL, Blumenstein BA, Crawford ED, A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 1991;325:1205-9
   PubMed Web of Science ®Google Scholar
• Mori K, Lamm DL, Crawford ED. A trial of bacillus Calmette-Guerin versus adriamycin in superficial bladder cancer: a South-West Oncology Group Study. Urol Int 1986;41:254-9
   PubMed Web of Science ®Google Scholar
• Prendergast G, Jaffe E. Cancer immunotherapy. Elsevier, Oxford, UK; 2007
   Google Scholar
• Hu X, Chakraborty NG, Sporn JR, Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996;56:2479-83
   PubMed Web of Science ®Google Scholar
• Nestle FO, Alijagic S, Gilliet M, Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Schwartzentruber DJ, Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-7
   PubMed Web of Science ®Google Scholar
• Tsang KY, Zaremba S, Nieroda CA, Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995;87(13):982-90
   PubMed Web of Science ®Google Scholar
• Petrella T, Quirt I, Verma S, Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev 2007;33:484-96
   PubMed Web of Science ®Google Scholar
• Schwartzentruber D, Lawson D, Richards J, A phase III multi-institutional randomized study of immunization with the gp100:209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. Proc Am Soc Clin Oncol 2009;27: abstract 9011
   Google Scholar
• Spitler LE, Weber RW, Allen RE, Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma. J Immunother 2009;32:632-7
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Neyns B, Linette G, Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11:155-64
   PubMed Web of Science ®Google Scholar
• Bornstein RS, Mastrangelo MJ, Sulit H, Immunotherapy of melanoma with intralesional BCG. Natl Cancer Inst Monogr 1973;39:213-20
   PubMedGoogle Scholar
• Emens LA. Cancer vaccines: on the threshold of success. Expert Opin Emerg Drugs 2008;13:295-308
   PubMed Web of Science ®Google Scholar
• Green DS, Bodman-Smith MD, Dalgleish AG, Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 2007;156:337-45
   PubMed Web of Science ®Google Scholar
• Ribas A, Comin-Anduix B, Jalil J, Combination of dendritic cell (DC) vaccination with CTLA4 blockade in patients (pts) with metastatic melanoma: a phase 1 clinical trial [abstract 2537]. AACR Meeting Abstracts 2008
   Google Scholar
• Stopeck AT, Hersh EM, Akporiaye ET, Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 1997;15:341-9
   PubMed Web of Science ®Google Scholar
• Small EJ, Schellhammer PF, Higano CS, Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94
   PubMed Web of Science ®Google Scholar
• Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene 2003;22:3188-92
   PubMed Web of Science ®Google Scholar
• Senzer NN, Kaufman HL, Amatruda T, Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009;27:5763-71
   PubMed Web of Science ®Google Scholar
• Radny P, Caroli UM, Bauer J, Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 2003;89:1620-6
   PubMed Web of Science ®Google Scholar
• Von Wussow P, Block B, Hartmann F, Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 1988;61:1071-4
   PubMed Web of Science ®Google Scholar
• Tan JK, Ho VC. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol 1993;19:985-90
   PubMedGoogle Scholar
• Si Z, Hersey P, Coates AS. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res 1996;6:247-55
   PubMed Web of Science ®Google Scholar
• Steinmann A, Funk JO, Schuler G, Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 2000;43:555-6
   PubMed Web of Science ®Google Scholar
• Foote MC, Burmeister BH, Thomas J, A novel treatment for metastatic melanoma with intralesional rose Bengal and radiotherapy: a case series. Melanoma Res 2010;20:48-51
   PubMed Web of Science ®Google Scholar
• Wiener M, Damian DL, Thompson JF. Systemic phototoxicity following intralesional rose bengal for subcutaneous melanoma metastases. Dermatology 2008;216:361-2
   PubMed Web of Science ®Google Scholar
• Robinson H. DNA vaccines. In: Austen F, Burakoff S, Rosen F, editors, Therapeutic immunology. 2nd edition. Wiley-Blackwell, Boston; 2001. p. 430-40
   Google Scholar
• Allovectin-7. Vical Incorporated. San Diego, CA. Available from: http://www.vical.com/products/cancer_therapies/allovectin-7.htm [Last accessed 27 March 2010]
   Google Scholar
• Galanis E. Technology evaluation: Allovectin-7, Vical. Curr Opin Mol Ther 2002;4:80-7
   PubMed Web of Science ®Google Scholar
• Plautz GE, Yang ZY, Wu BY, Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 1993;90:4645-9
   PubMed Web of Science ®Google Scholar
• Nabel GJ, Gordon D, Bishop DK, Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA 1996;93:15388-93
   PubMed Web of Science ®Google Scholar
• Rini BI, Selk LM, Vogelzang NJ. Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin Cancer Res 1999;5:2766-72
   PubMed Web of Science ®Google Scholar
• Horton HM, Dorigo O, Hernandez P, IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile. J Immunol 1999;163:6378-85
   PubMed Web of Science ®Google Scholar
• Zhao H, Hemmi H, Akira S, Contribution of Toll-like receptor 9 signaling to the acute inflammatory response to nonviral vectors. Mol Ther 2004;9:241-8
   PubMed Web of Science ®Google Scholar
• Parker SE, Vahlsing HL, Serfilippi LM, Cancer gene therapy using plasmid DNA: safety evaluation in rodents and non-human primates. Hum Gene Ther 1995;6:575-90
   PubMed Web of Science ®Google Scholar
• Lew D, Parker SE, Latimer T, Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice. Hum Gene Ther 1995;6:553-64
   PubMed Web of Science ®Google Scholar
• Horn NA, Meek JA, Budahazi G, Cancer gene therapy using plasmid DNA: purification of DNA for human clinical trials. Hum Gene Ther 1995;6:565-73
   PubMed Web of Science ®Google Scholar
• Nabel GJ, Nabel EG, Yang ZY, Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993;90:11307-11
   PubMed Web of Science ®Google Scholar
• Silver H, Klassa R, Bally J, Phase I gene therapy of HLA-B7 transduction by direct injection in malignant melanoma [abstract 2337]. AACR Meeting Abstracts 1996
   Google Scholar
• Rubin J, Galanis E, Pitot HC, Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Gene Ther 1997;4:419-25
   PubMed Web of Science ®Google Scholar
• Gleich LL, Gluckman JL, Armstrong S, Alloantigen gene therapy for squamous cell carcinoma of the head and neck: results of a Phase-1 trial. Arch Otolaryngol Head Neck Surg 1998;124:1097-104
   PubMed Web of Science ®Google Scholar
• Hersh EM, Stopeck A, Klassa R, Allovectin-7 (hla-b7/[beta]2m plasmid dna/lipid complex) therapy in metastatic malignant melanoma, Phase II studies. Proc Am Soc Clin Oncol 1998;17: abstract 1658
   Google Scholar
• Stopeck AT, Jones A, Hersh EM, Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res 2001;7:2285-91
   PubMed Web of Science ®Google Scholar
• Richards J, Bedikian A, Gonzalez R, High-dose Allovectin-7 in patients with advanced metastatic melanoma: final Phase 2 data and design of Phase 3 registration trial. Proc Am Soc Clin Oncol 2005;23: abstract 7543
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Richards J, Kharkevitch D, A phase 2 study of high-dose allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res 2010 (In Press)
   Web of Science ®Google Scholar
• Gonzalez R, Hutchins L, Nemunaitis J, Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res 2006;16:521-6
   PubMed Web of Science ®Google Scholar
• Gleich LL, Gluckman JL, Nemunaitis J, Clinical experience with HLA-B7 plasmid DNA/lipid complex in advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2001;127:775-9
   PubMed Web of Science ®Google Scholar
• Richards J, Thompson J, Atkins M, A controlled, randomized phase III trial comparing the response to dacarbazine with and without Allovectin-7 in patients with metastatic melanoma. Proc Am Soc Clin Oncol 2002;21: abstract 1380
   Google Scholar
• Bedikian AY, Del Vecchio M. Allovectin-7 therapy in metastatic melanoma. Expert Opin Biol Ther 2008;8:839-44
   PubMed Web of Science ®Google Scholar
• Vical Incorporated. A Phase 3 clinical trial to evaluate the safety and efficacy of treatment with 2 mg intralesional Allovectin-7 Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in subjects with recurrent metastatic melanoma. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00395070 [Last accessed 27 March 2010] NLM Identifier: NCT00395070
   Google Scholar
• Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-49
   PubMed Web of Science ®Google Scholar
• Atkins MB, Hsu J, Lee S, Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008;26:5748-54
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Millward M, Pehamberger H, Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006;24:4738-45
   PubMed Web of Science ®Google Scholar
• Quirt I, Verma S, Petrella T, Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist 2007;12:1114-23
   PubMed Web of Science ®Google Scholar
• Hauschild A, Agarwala SS, Trefzer U, Results of a Phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27:2823-30
   PubMed Web of Science ®Google Scholar
• Flaherty K, Puzanov I, Sosman J, Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. Proc Am Soc Clin Oncol 2009;27: abstract 9000
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Chapman PB, Wolchok JD, A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. Proc Am Soc Clin Oncol 2009;27: abstract 9001
   Web of Science ®Google Scholar
• Sarnaik AA, Weber JS. Recent advances using anti-CTLA-4 for the treatment of melanoma. Cancer J 2009;15:169-73
   PubMed Web of Science ®Google Scholar
• Sznol M. Betting on immunotherapy for melanoma. Curr Oncol Rep 2009;11:397-404
   PubMed Web of Science ®Google Scholar
• Lee SC, Lopez-Albaitero A, Ferris RL. Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies. Curr Oncol Rep 2009;11:156-62
   PubMed Web of Science ®Google Scholar
• Wu AA, Niparko KJ, Pai SI. Immunotherapy for head and neck cancer. J Biomed Sci 2008;15:275-89
   PubMed Web of Science ®Google Scholar